Stroke and atherothrombosis: an update on the role of antiplatelet therapy

Area of Science:

• Cardiovascular Medicine
• Neurology
• Pharmacology

Background:

• Atherothrombosis underlies most acute ischemic events, including stroke, posing significant recurrence risks.
• Patients with atherothrombosis in one vascular area face heightened vulnerability to events elsewhere.
• High rates of diabetes and obesity in patients with prior cardiovascular events underscore the need for effective prevention.

Purpose of the Study:

• To review current guidelines for preventing atherothrombotic events.
• To focus on the role of oral antiplatelet agents in managing patients with ischemic stroke.

Main Methods:

• Review of existing literature and clinical guidelines on atherothrombosis prevention.
• Analysis of data from studies like the CHARISMA trial regarding antiplatelet therapy efficacy.
• Focus on oral antiplatelet agents, including dual therapy with aspirin and clopidogrel.

Main Results:

• Atherothrombosis is a major cause of ischemic stroke and cardiovascular events.
• Dual antiplatelet therapy (aspirin and clopidogrel) may benefit specific stroke patient populations, though not primary prevention.
• Oral antiplatelet agents are crucial for preventing recurrent atherothrombotic events.

Conclusions:

• Oral antiplatelet therapy is a cornerstone in preventing atherothrombotic events, particularly in patients with ischemic stroke.
• Further research may clarify optimal antiplatelet strategies for high-risk populations.
• Effective management of risk factors like diabetes and obesity is vital alongside antiplatelet therapy.